Skip to main content
. Author manuscript; available in PMC: 2016 Dec 9.
Published in final edited form as: Future Oncol. 2011 Sep;7(9):1035–1043. doi: 10.2217/fon.11.81

Table 1.

The most frequent nonhematologic toxic effects of ruxolitinib therapy in a Phase I/II clinical trial.

Nonhematologic toxic effect Occurrence (%)
Diarrhea 5.9
Fatigue 4.3
Headache 3.3
Peripheral edema 2.6
Pain in extremities 2.6
Urinary tract infection 2.6
Dizziness 2.6